Table 2.

Basic characteristics of the studied genetic variants.

SNP	Variant type	Gene	Base change	NCBI assembly location (Build GRCh38)a	TaqMan SNP assay ID	MAFb
						GBM patients	Control group	ALL	EUR	CEU
rs1047972	Missense	AURKA	C/T	Chr.20:56386407	AHX1IRW	0.162	0.146	0.150	0.182	0.157
rs2273535	Missense	AURKA	A/T	Chr.20:56386485	C_25623289_10	0.299	0.238	0.310	0.216	0.177
rs8173	3′ UTR	AURKA	G/C	Chr.20:56369735	C_8947675_10	0.354	0.305	0.486	0.282	0.232
rs911160	Intron	AURKA	G/C	Chr.20:56382507	C_8947670_10	0.300	0.276	0.447	0.246	0.202
rs2289590	Intron	AURKB	C/A	Chr.17:8207446	C_15770418_10	0.375	0.415	0.453	0.415	0.389
rs2241909	Synonymous	AURKB	A/G	Chr.17:8205021	C_22272900_10	0.332	0.332	0.379	0.340	0.303
rs11084490	5′ UTR	AURKC	C/G	Chr.19:57231104	C_27847620_10	0.152	0.223	0.132	0.165	0.177
rs758099	Intron	AURKC	C/T	Chr.19:57231966	C_2581008_1_	0.162	0.302	0.375	0.255	0.253
rs42873	Intron	PLK1	G/C	Chr.16:23683411	C_2392140_10	0.354	0.208	0.234	0.215	0.192

ALL all phase 3 individuals, CEU Utah residents with Northern and Western European ancestry, EUR European population, GBM glioblastoma multiforme, MAF minor allele frequency, SNP single nucleotide polymorphism, UTR untranslated region. ^ahttps://www.lifetechnologies.com. ^bMAFs extracted from 1000 Genomes Project Phase 3.